Gilead
Research
Research
Our growing pipeline includes novel investigational medications for the potential treatment of life-threatening diseases in the areas of unmet medical need.

Recent News

Visit Gilead’s newsroom for access to our most recent news.

At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs currently focus on potential treatments in the following therapeutic areas:

HIV/AIDS

"Quad" Integrase STR (elvitegravir/FTC/TDF/cobicistat)
Potential Indication: HIV/AIDS
U.S. and EU Approvals Submitted
Elvitegravir (integrase inhibitor)
Potential Indication: HIV/AIDS
Phase 3
Cobicistat (formerly GS-9350) (PK enhancer)
Potential Indication: HIV/AIDS
Phase 3
GS-7340 (nucleotide reverse transcriptase inhibitor)
Potential Indication: HIV/AIDS
Phase 2

 

Liver Disease

GS-7977 (nucleotide NS5B inhibitor)
Potential Indication: Hepatitis C
Phase 3
GS-6624 (monoclonal antibody)
Potential Indication: Liver Fibrosis
Phase 2
Tegobuvir/GS-9190 (non-nucleoside NS5B inhibitor)
Potential Indication: Hepatitis C
Phase 2
GS-9256 (NS3 protease inhibitor)
Potential Indication: Hepatitis C
Phase 2
GS-9451 (NS3 protease inhibitor)
Potential Indication: Hepatitis C
Phase 2
GS-5885 (NS5A inhibitor)
Potential Indication: Hepatitis C
Phase 2
GS-9620 (TLR-7 agonist)
Potential Indication: Hepatitis C / Hepatitis B
Phase 1
GS-9669 (non-nucleoside polymerase inhibitor)
Potential Indication: Hepatitis C
Phase 1

 

Cardiovascular/Metabolic

Ranolazine (late sodium current inhibitor)
Potential Indication: Incomplete Revascularization Post-PCI
Phase 3
Ranolazine (late sodium current inhibitor)
Potential Indication: Potential Indication: Type 2 Diabetes
Phase 3

 

Respiratory

Aztreonam for Inhalation Solution
Potential Indication: Bronchiectasis
Phase 3
GS-6624 (monoclonal antibody)
Potential Indication: Idiopathic Pulmonary Fibrosis
Phase 1

 

Inflammation/Oncology

GS-1101 (PI3K delta inhibitor)
Potential Indication: Chronic Lymphocytic Leukemia
Phase 3
GS-1101 (PI3K delta inhibitor)
Potential Indication: Indolent non-Hodgkin’s Lymphoma
Phase 2
GS-6624 (monoclonal antibody)
Potential Indication: Colorectal Cancer
Phase 2
GS-6624 (monoclonal antibody)
Potential Indication: Myelofibrosis
Phase 2
GS-6624 (monoclonal antibody)
Potential Indication: Pancreatic Cancer
Phase 2
GS-9973 (Syk Inhibitor)
Potential Indication: Rheumatoid Arthritis
Phase 1